Alzheimer's News Today Home | Alzheimer's News Today
网页2024年9月23日 — If you’re diagnosed with dementia or its most common form, Alzheimer’s disease, please know that however you feel about it is how you feel about it. Your feelings are valid. Someone diagnosed with dementia commented on a recent column of mine, “We must avoid wallowing in self-pity…. September 19, 2024 News by Margarida Maia, PhD.
FDA approves donanemab, now Kisunla, to treat early Alzheimer's
网页2024年7月3日 — The U.S. Food and Drug Administration (FDA) has approved Eli Lilly ‘s antibody therapy donanemab, now Kisunla, for certain adults with Alzheimer’s disease. Specifically, Kisunla is indicated for patients with early symptomatic Alzheimer’s — to include individuals with mild cognitive impairment or mild dementia, and confirmed evidence of ...
Biomarker test to diagnose Alzheimer's wins FDA breakthrough...
网页2024年5月2日 — The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to Elecsys Phospho-Tau 217 (pTau217), a blood-based biomarker test that can help distinguish Alzheimer’s disease from other neurodegenerative disorders. The test, developed by Roche in collaboration with Eli Lilly, is …
Alzheimer's therapy foralumab nasal spray cleared by FDA for...
网页2024年7月11日 — Foralumab, an investigational nasal spray being developed by Tiziana Life Sciences, has been cleared by the U.S. Food and Drug Administration (FDA) for expanded use to treat moderate Alzheimer’s disease, and the first patient is expected to be dosed soon. An expanded use program, also called a compassionate use program, gives a …
Simufilam aids cognition in 47% of Alzheimer's patients in Phase 2...
网页2023年3月14日 — The Phase 2 trial runs for two years, with treatment safety and tolerability being measured over that time. Enrolled patients are randomized to a full two years of simufilam at 100 mg twice daily, or to one open-label year of treatment followed by six months of a placebo tablet (months 12 to 18), before returning to the treatment for a …
Alzheimer’s blood test gets FDA breakthrough device designation
网页2024年3月14日 — by Margarida Maia, PhD March 14, 2024. The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to Quanterix ’s experimental blood test measuring p-Tau 217, the protein that builds up as toxic tangles in the brains of people with Alzheimer’s disease. The test, Simoa p-Tau 217, has the potential to help doctors ...
Lecanemab Slows Dementia of Early Alzheimer’s in Phase 3 Trial
网页2022年10月4日 — The trial also met key secondary goals, with lecanemab outperforming placebo at reducing plaque levels and on other measures of disease severity, namely the Alzheimer’s Disease Assessment Scale-cognitive subscale14 (ADAS-cog14), Alzheimer’s Disease Composite Score (ADCOMS) and the Alzheimer’s Disease Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS ...
ALZ-801 for 2 years seen to sustain cognition in early Alzheimer’s
网页2023年9月22日 — These are the top-line findings of an ongoing Phase 2 clinical trial (NCT04693520), whose two-year data also showed that Alzheon’s experimental therapy preserved the hippocampus, a brain structure important for memory that is damaged first in Alzheimer’s.. Importantly, ALZ-801’s safety profile over two years continued to show no increased risk of brain swelling and bleeds, which have ...
Topline results of Phase 3 studies of simufilam for Alzheimer's...
网页2024年2月8日 — Two Phase 3 clinical trials are testing the effectiveness of simufilam, an experimental oral therapy that’s designed to improve cognition in people with Alzheimer’s disease.. Top-line results from the RETHINK-ALZ trial (NCT04994483) are expected by the end of this year, according to simufilam’s developer Cassava Sciences.Results from the second study, REFOCUS-ALZ study (NCT05026177), are ...
News Archives - Alzheimer's News Today
网页Zunveyl, therapy that may be easier on GI system, wins FDA approval. The U.S. Food and Drug Administration (FDA) has approved the oral therapy Zunveyl (benzgalantamine), previously known as ALPHA-1062, to treat mild-to-moderate Alzheimer’s disease. “The approval of Zunveyl is a pivotal moment in the fight against Alzheimer’s disease as it ...
跳至内容